DOCSLIB.ORG

Depression in Adults: Treatment and Management

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Depression in Adults: Treatment and Management Depression in adults: treatment and management Appendix J11: study characteristics for evidence from previous versions of the guideline (St John’s wort, seasonal affective disorder and relapse prevention) Depression in adults: Appendix J11 1 Contents Treatment of a new depressive episode ................................................................................................. 3 St John’s wort - studies in 2004 guideline ........................................................................................... 3 Seasonal affective disorder ................................................................................................................. 8 Light therapy - new studies in the guideline update ...................................................................... 8 Non-light therapy interventions for depression with a seasonal pattern/SAD ............................ 31 Relapse prevention ............................................................................................................................... 35 2004 Guideline .............................................................................................................................. 35 2009 Guideline .............................................................................................................................. 40 Seasonal affective disorder ............................................................................................................... 49 Non-light therapy interventions for depression with a seasonal pattern/SAD - relapse prevention ..................................................................................................................................... 49 Depression in adults: Appendix J11 2 1 Treatment of a new depressive episode 2 St John’s wort - studies in 2004 guideline 3 Characteristics of included studies 4 Study Methods Participants Interventions Outcomes Notes A C Behnke2002 Y Allocation: Random (no Inpatients and outpatients. Age: 18-73. St John's wort (300mg = 2 x 150mg HRSD-17 mean change scores B M C A details) Duration: 6 N=70. Diagnosis: ICD-10 Hypericum perforatum: 0.450- Non-responders (patients not achieving weeks Analysis: 0.495mg total hypericin per tablet) Depression (F32), HRSD≥16 and completer ≥50% decrease in HRSD) Fluoxetine (40mg) ≤24. Mean baseline HRSD: SJW - 20 +- Leaving the study early 3.2, Fluoxetine - 20.7 +-2.9. Patients reporting adverse effects Bergmann93 Y Allocation: Random (no Outpatients. Age: 25-83. N= 80. St John's wort HRSD-17 mean endpoint scores B O I A details) Duration: 6 Diagnosis: ICD-10 mild- moderate Amitriptyline Leaving the study early weeks Analysis: ITT depressive episode. Mean baseline HRSD: SJW - Leaving the study early due to side effects 15.82 +-0.70, amitriptyline - 15.26 Patients reporting adverse effects +-0.74 Non-responders (patients not achieving ≥50% decrease in HRSD) Brenner00 Y O Allocation: Random (no Outpatients. Age: 18-65. N=30. Diagnosis: St John's wort (600mg -> 900mg LI HRSD-17 mean endpoint scores Dose of sertraline was B I A/L details) Duration: 7 DSM-IV major depression recurrent (21 160) below the therapeutic Non-responders (patients not achieving weeks Analysis: ITT patients) or single episode (9 patients) level. Sertraline (50mg -> 75mg) and HRSD≥17, baseline HRSD=21.5+-3.1 ≥50% decrease in HRSD) Leaving the study early Leaving the study early due to side effects Davidson02 Allocation: Random (no Outpatients. Age: 18+. N=340. Diagnosis: St John's wort (900 up to 1500mg HRSD-17 mean change scores Dose of sertraline was B YOI A/L P details) Duration: 8 DSM-IV major depressive disorder and LI 160: standardised to 0.12-0.28% below the therapeutic Non-responders (patients not achieving ≥50 decrease in HRSD weeks Analysis: ITT - HRSD- 17≥20, baseline = 22.5-23.1 hypericin) level and 12≥HRSD≥9) LOCF Sertraline (50mg up to 100mg) Non-remitters (patients not achieving HRSD Placebo ≤ 8) Leaving the study early Leaving the study early due to side effects Depression in adults: Appendix J11 3 Study Methods Participants Interventions Outcomes Notes A C Hansgen1996 Allocation: Random (no Outpatients and primary care patients. 1. St John's wort (900mg = 1. HRSD mean endpoint scores B Y M C P details) Duration: 4 N=108. Age: 18-70. Diagnosis: DSM-III-R 3x300mg LI 160) Non-responders (patients not achieving weeks Analysis: major depression, HRSD≥16. 2. Placebo completer ≥50% decrease in HRSD) Leaving the study early Patients reporting adverse effects Harrer94 Y O C Allocation: Random (no Outpatients. N=102. Age: 24-65. St John's wort (900mg = 3x 300mg HRSD-17 mean endpoint scores Dose of maprotiline was B A/L details) Duration: 4 Diagnosis: ICD-10 Moderate depressive LI 160) below the therapeutic Non-responders (patients not achieving weeks Analysis: episode, HRSD- 17≥16. Mean baseline level Maprotiline (75mg) Completers HRSD: SJW - 20.5, maprotiline - 21.5 ≥50% decrease in HRSD or HRSD≤10) Leaving the study early due to side effects Leaving the study early Patients reporting adverse effects Harrer99 E O I Allocation: Random (no Outpatients. N=161. Age: 60-80. St John's wort (800mg = 4 x 200mg HRSD-17 mean endpoint scores ITT sample=149. B A details) Duration: 6 Diagnosis: ICD-10 mild- moderate LoHyp-57: drug extract ratio 5-7:1) Non-responders (patients not achieving HRSD≤10 or >=50% weeks Analysis: ITT - depressive episode, baseline HRSD 16.6- Fluoxetine (20mg) decrease in HRSD) LOCF 17.18 Leaving the study early Leaving the study early due to side effects Patients reporting adverse effects Kalb2001 Y O I Allocation: Random (no Outpatients. N=72. Age: 18-65. Diagnosis: St John's wort (900mg = 3 x 300mg HRSD-17 mean change scores B P details) Duration: 6 DSM-IV mild- moderate major depression WS5572: drug extract ratio 2.5-5:1, Non-responders (patients not achieving weeks Analysis: ITT and HRSD≥16. Mean baseline HRSD: 5% hyperforin) SJW - 19.7 +-3.4, range 16-34; ≥50% decrease in HRSD) Placebo placebo - 20.1 +-2.6, range 16-26. Leaving the study early Leaving the study early due to side effects Patients reporting adverse effects Laakmann98 Y Allocation: Random (no Outpatients. N=147. Age: 18-65. St John's wort (900mg = 3 x 300mg HRSD-17 mean change score Data extracted for B O I P details) Duration: 6 Diagnosis: DSM-IV mild or moderate WS5572: 5% hyperforin) higher dose SJW (1) Non-responders (patients not achieving weeks Analysis: LOCF depression and HRSD-17≥17. Mean and placebo (3). St John's wort (900mg = 3 x 300mg baseline HRSD: SJW - 20.9 +-3.1, ≥50% decrease in HRSD) WS5573: 0.5% hyperforin) placebo Leaving the study early Placebo - 21.2 +-3.3 Leaving the study early due to side effects Patients reporting adverse effects Depression in adults: Appendix J11 4 Study Methods Participants Interventions Outcomes Notes A C Lecrubier02 Y Allocation: Random (no Outpatients. Age: 18-66. N=375. 1 St John's wort (900mg = 3 x HRSD-17 mean change scores B O I P details) Duration: 6 Diagnosis: DSM-IV mild - moderate 300mg WS5570: 0.12- Non-responders (patients not achieving weeks Analysis: ITT - depression and 25=>HRSD≥18, baseline 0.28% hypericin) LOCF = 21.9 ≥50% decrease in HRSD) 2. Placebo +-1.7, range: 18-27 Leaving the study early Leaving the study early due to side effects Non-remitters (patients not achieving HRSD≤6) Patients reporting adverse effects Philipp99 Y O I Allocation: Random (no Primary care patients(?). N=263. Age: 18- 1. St John's wort (1050mg = 3 x 1. HRSD-17 mean change scores A P details) Duration: 8 65, mean=47. Diagnosis: ICD-10 350mg STEI 300: 0.2- 0.3% weeks Analysis: ITT - moderate depressive episode and HRSD- hypericin, 2-3% hyperforin) 2. Non-responders (patients not achieving ≥50% decrease in LOCF 17 ≥18, baseline=22.6 +-4.1 HRSD) 2. Imipramine (50mg -> 100mg) 3. Leaving the study early 3. Placebo 4. Leaving the study early due to side effects Philipp99 Y O I Allocation: Random (no Primary care patients(?). N=263. Age: 18- 1. St John's wort (1050mg = 3 x 5. HRSD-17 mean change scores A P details) Duration: 8 65, mean=47. Diagnosis: ICD-10 350mg STEI 300: 0.2- 0.3% 4. Patients reporting adverse effects weeks Analysis: ITT - moderate depressive episode and HRSD- hypericin, 2-3% hyperforin) 6. Non-responders (patients not achieving ≥50% decrease in LOCF 17 ≥18, baseline=22.6 +-4.1 HRSD) 5. Imipramine (50mg -> 100mg) 7. Leaving the study early 6. Placebo 8. Leaving the study early due to side effects Schrader00 Y Allocation: Random (no Outpatients. N=240. Age: 18+, mean = St John's wort (500mg = 2 x 250mg HRSD-21 mean change scores B O I A details) Duration: 6 56.5. N=240. Diagnosis: mild - moderate ZE117 (drug extract ratio 4-7:1) Patients reporting adverse effects 7. Non-responders (patients not achieving HRSD≤10 or ≥50% weeks Analysis: ITT - depressive episode, 24≥HRSD≥16, mean Fluoxetine (20mg) decrease in HRSD) LOCF HRSD = 19.5-19.65 Leaving the study early due to side effects Patients reporting adverse effects Schrader98 Y Allocation: Random (no N=162. Age: 18+. Diagnosis: ICD-10 mild St John's wort (500mg = 2 x 200mg HRSD-21 mean change scores B details) Duration: 6 or moderate depressive episode and 16=< ZE117: 0.5mg hypericin) ? I P Non-responders (patients not achieving weeks Analysis: ITT HRSD≤24. Mean baseline HRSD: SJW - Placebo 20.13, placebo - 18.76 ≥50% decrease in HRSD or HRSD≤10) Patients reporting adverse effects Depression in adults: Appendix J11 5 Study Methods Participants Interventions Outcomes Notes A C Shelton 2001 Y Allocation: Random (no Outpatients. N=200. Age: 18+. Diagnosis:
Load more

Recommended publications
  • The Effect of Bright Light on Affiliation
    THE EFFECT OF ACUTE BRIGHT LIGHT EXPOSURE ON SOCIAL AFFILIATION By Copyright 2014 YEVGENY BOTANOV Submitted to the graduate degree program in Psychology and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. ________________________________________ Chairperson Stephen S. Ilardi, PhD ________________________________________ Monica Biernat, PhD ________________________________________ Rick E. Ingram, PhD ________________________________________ Sarah B. Kirk, PhD ________________________________________ Kyeung Hae Lee, PhD Date Defended: July 02, 2014 ii The Dissertation Committee for Yevgeny Botanov certifies that this is the approved version of the following dissertation: THE EFFECT OF ACUTE BRIGHT LIGHT EXPOSURE ON SOCIAL AFFILIATION ________________________________________ Chairperson Stephen S. Ilardi, PhD Date Approved: July 02, 2014 iii Abstract In recent decades, bright light has emerged as a useful tool in numerous clinical and non-clinical applications, with the potential to influence circadian rhythms, sleep, mood, and several other functional domains. However, despite the existence of plausible neurological pathways through which light could also influence social behavior, little is known at this point about the direct effects of bright light exposure on social interaction. Accordingly, the present study – utilizing a sample of young adults endorsing at least mild seasonal fluctuations in clinically relevant domains – examined the acute effects
    [Show full text]
  • Seasonal Changes in Mood and Behavior Among Diverse
    SEASONAL CHANGES IN MOOD AND BEHAVIOR AMONG CHILDREN AND ADOLESCENTS DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By Katharine Davies Smith, M.A. ***** The Ohio State University 2005 Dissertation Committee: Dr. Mary Fristad, Advisor Approved by Dr. Steven Beck ______________________ Dr. Michael Vasey Advisor Dr. Nancy Ryan-Wenger Department of Psychology Copyright by Katharine Davies Smith 2005 ABSTRACT Seasonal mood disorder (SMD) is likely prevalent among children and adolescents; however, there are few empirical investigations of pediatric SMD in the literature. To contribute to the field, the current study investigates the seasonality of mood and behavior among children and adolescents using longitudinal data collected from 1987 to 1998. One hundred eleven youths diagnosed with depression, 369 bereaved youths, 129 community controls, and their parents completed individual assessments at baseline, five, thirteen, and twenty-five months later. Assessment materials include several measures of depressive symptoms and diagnostic instruments. Multilevel analyses were conducted using MlwiN software. According to both parent- and child-report, youths from all three groups earn significantly higher total scores on measures of depression during the winter than the summer. On the other hand, significant seasonal effects do not arise for a measure of overall psychopathology. This implies that seasonality is limited to mood disorders. While this seasonal effect is significant, actual changes of mean scores on measures of depression from the summer to the winter are minimal, suggesting that season may have little affect on the mood and behavior for the majority of participants from each group.
    [Show full text]
  • Bright Light Therapy for Bipolar Depression
    Bright light therapy for bipolar depression Evidence suggests efficacy as an adjunctive treatment right light therapy (BLT) refers to the use of bright light to treat symptoms of depression. BLT was initially pre- scribed as a treatment for patients with seasonal affec- B 1 tive disorder. It was later found helpful for nonseasonal depression,2 premenstrual dysphoric disorder, postpartum depression, and phase shift circadian disorders, including for patients with dementia whose cognitive function improved after treatment with BLT.3 More recent studies suggest year- round benefit for nonseasonal depression.2 The American Psychiatric Association practice guidelines for the treatment of depression list BLT as an alternative and/or addition to pharmacologic and psychological treatment.4 BLT also may be beneficial for patients who are in the depressive phase of bipolar illness. This article describes the evidence, rationale for use, ANDRZEJ WOJCICKI mechanism of action, benefits, and safety profile of BLT for Suhayl J. Nasr, MD Ahmed Z. Elmaadawi, MD treating patients with bipolar depression. Professor of Psychiatry Adjunct Assistant Professor Indiana University School of Psychiatry of Medicine Indiana University School Indianapolis, Indiana of Medicine Circadian rhythm disruption in bipolar disorder Chief of Behavioral Indianapolis, Indiana Clinical manifestation. Patients with bipolar disorder (BD) Health Services Director of Interventional spend more time in depression than in mania.5 Sleep distur- Beacon Health System Psychiatry Division South Bend, Indiana Beacon Health System bance is a core symptom of BD; patients typically have little South Bend, Indiana need for sleep during a manic episode, and excess sleepiness Rikinkumar Patel, MD, during a depressive episode.
    [Show full text]
  • Photobiomodulation and the Brain: a New Paradigm
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author J Opt. Author Manuscript Author manuscript; Manuscript Author available in PMC 2018 January 01. Published in final edited form as: J Opt. 2017 January ; 19(1): 013003–. doi:10.1088/2040-8986/19/1/013003. Photobiomodulation and the brain: a new paradigm Madison Hennessy1 and Michael R Hamblin2,3,4 1Briarcliff High School, Briarcliff Manor, NY, USA 2Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA, USA 3Department of Dermatology, Harvard Medical School, Boston, MA, USA 4Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA, USA Abstract Transcranial photobiomodulation (PBM) also known as low level laser therapy (tLLLT) relies on the use of red/NIR light to stimulate, preserve and regenerate cells and tissues. The mechanism of action involves photon absorption in the mitochondria (cytochrome c oxidase), and ion channels in cells leading to activation of signaling pathways, up-regulation of transcription factors, and increased expression of protective genes. We have studied PBM for treating traumatic brain injury (TBI) in mice using a NIR laser spot delivered to the head. Mice had improved memory and learning, increased neuroprogenitor cells in the dentate gyrus and subventricular zone, increased BDNF and more synaptogenesis in the cortex. These highly beneficial effects on the brain suggest that the applications of tLLLT are much broader than at first conceived. Other groups have studied stroke (animal models and clinical trials), Alzheimer’s disease, Parkinson’s disease, depression, and cognitive enhancement in healthy subjects. Keywords Transcranial photobiomodulation; low level laser therapy; brain disorders; traumatic brain injury; stroke; Alzheimer’s disease; psychiatric diseases 1 Introduction Light in the visible and near-infrared spectrum makes up the major part of solar radiation and is also provided by artificial light sources.
    [Show full text]
  • The Use of Bright Light in the Treatment of Insomnia
    Chapter e39 The Use of Bright Light in the Treatment of Insomnia Leon Lack and Helen Wright Department of Psychology, Flinders University, Adelaide, South Australia PROTOCOL NAME The use of bright light in the treatment of insomnia. GROSS INDICATION Certain types of insomnia that are associated with abnormal timing of circa- dian rhythms may be treated with bright light therapy. SPECIFIC INDICATION Some individuals with sleep onset insomnia experience difficulty falling asleep at a “normal time” but no difficulty maintaining sleep once it is initi- ated. Individuals with this type of insomnia may have a delayed or later timed circadian rhythm. Bright light therapy timed in the morning after arising can advance or time circadian rhythms earlier and thus would be indicated for sleep onset or initial insomnia. Morning bright light therapy is also indicated for the related problem of delayed sleep phase disorder. Individuals experiencing early morning awakening insomnia have no diffi- culty initiating sleep but their predominant difficulty is waking before intended and not being able to resume sleep. These individuals may have an advanced or early timed circadian rhythm. Bright light therapy in the evening before sleep would be indicated for this type of insomnia as well as for the more extreme version, advanced sleep phase disorder. CONTRAINDICATIONS Bright light therapy would not be recommended in the following cases: ● Insomnia in which there is no indication of abnormal timing of circadian rhythms (e.g. combined problem initiating and maintaining sleep, having no strong morning or evening activity preferences) Behavioral Treatments for Sleep Disorders. DOI: 10.1016/B978-0-12-381522-4.00053-5 © 2011 Elsevier Inc.
    [Show full text]
  • Light Therapy and Seasonal Affective Disorder (SAD)
    Standard Research Article Psychother Psychosom 2020;89:17–24 Received: May 23, 2019 DOI: 10.1159/000502891 Accepted after revision: August 22, 2019 Published online: October 1, 2019 The Efficacy of Light Therapy in the Treatment of Seasonal Affective Disorder: A Meta-Analysis of Randomized Controlled Trials a a a, b a c Edda Pjrek Michaela-Elena Friedrich Luca Cambioli Markus Dold Fiona Jäger a a a a Arkadiusz Komorowski Rupert Lanzenberger Siegfried Kasper Dietmar Winkler a Department of Psychiatry and Psychotherapy, Medical University of Vienna, Vienna, Austria; b Competence Center for Eating Behavior, Obesity and the Psyche, Zofingen Hospital, Zofingen, Switzerland; c University Medical Center Freiburg, University of Freiburg, Freiburg, Germany Keywords moderate heterogeneity of the studies and a moderate-to- Seasonal affective disorder · Winter depression · high risk of bias. Conclusions: BLT can be regarded as an ef- Bright light therapy · Meta-analysis fective treatment for SAD, but the available evidence stems from methodologically heterogeneous studies with small- to-medium sample sizes, necessitating larger high-quality Abstract clinical trials. © 2019 S. Karger AG, Basel Background: Bright light therapy (BLT) has been used as a treatment for seasonal affective disorder (SAD) for over 30 years. This meta-analysis was aimed to assess the efficacy of BLT in the treatment of SAD in adults. Method: We per- Introduction formed a systematic literature search including randomized, single- or double-blind clinical trials investigating BLT Seasonal affective disorder (SAD) is a subtype of recur- ( 1,000 lx, light box or light visor) against dim light ( 400 lx) ≥ ≤ rent major depressive or bipolar disorder defined by a or sham/low-density negative ion generators as placebo.
    [Show full text]
  • Light Therapy and the Management of Winter Depression John M
    Advances in PsychiatricLight therapy Treatment in seasonal (2004), affective vol. 10, disorder233–240 Light therapy and the management of winter depression John M. Eagles Abstract Much the most common type of seasonal affective disorder at temperate latitudes is recurrent winter depression, which probably affects around 3% of adults in the UK to a clinically significant degree. In this article, diagnosis and presentation are discussed and symptoms are contrasted with those of non- seasonal depression. Aetiology and epidemiology, with regard to age, gender and latitude of residence, are described. Sufferers are often treated with light therapy, and this is described in some detail, with mention of effectiveness, prediction of outcome, timescales of response, side-effects, use of lightboxes and alternatives to lightboxes. Other general aspects of the management of seasonal affective disorder, including the use of antidepressant medication, are also outlined. The main purpose of this article is to discuss the profound melancholia has supervened, which in use of light therapy in seasonal affective disorder. spring passes into mania, which again in autumn There are two recognised forms of this disorder. gradually gives way to melancholia’. In the Recurrent summer depressions occur in people modern era, it was in 1984 that Rosenthal et al living close to the equator, but are very rare in those published their seminal paper describing a group who live in temperate climates. This article focuses of patients with seasonal affective disorder and the solely on recurrent winter depression, which is beneficial effects of bright artificial light on patients’ common at temperate latitudes, and for which light symptoms.
    [Show full text]
  • LIGHT THERAPY for MAJOR DEPRESSION a Game Changer for Physicians
    34 North Seventh Street Center for Suite NPH2-E Environmental Brooklyn, NY 11249-3793 Therapeutics www.cet.org a 501(c)(3) nonprofit foundation 646-837-7337 LIGHT THERAPY FOR MAJOR DEPRESSION A Game Changer for Physicians An ambitious 2016 study in JAMA Psychiatry has compared SSRI and light treatment for Major Depressive Disorder (MDD). This brochure shows how you can use that research to enhance your treatment of MDD with three essential tips and a set of online resources for clinicians. While light therapy for seasonal affective disorder has taken its place in clinical practice with endorsement by an American Psychiatric Association task force, only a few exploratory studies supported its efficacy for nonseasonal depression ― until now. The verdict came with the new eight-week, randomized, placebo- controlled multicenter study of 122 outpatients. Raymond W. Lam, MD, of the University of British Columbia, directed the trial in association with Toronto colleagues Anthony J. Levitt, MD, and Robert D. Levitan, MD. The Ray Lam investigators compared two treatments for MDD, tested against two placebos. The results were clear: Light therapy and the combination of light therapy with an antidepressant were superior to the antidepressant alone by a large margin. The patients were randomly assigned to one of four groups: Light and antidepressant combination treatment: light therapy (10,000 lux fluorescent white light early in the morning for 30 minutes), plus fluoxetine 20 mg Light only: light therapy plus “dummy” pills Antidepressant only: fluoxetine 20 mg, plus an inactivated negative ion generator that hummed as if it were working Placebos: dummy pills and the inactivated ion generator Copyright © 2016, Center for Environmental Therapeutics.
    [Show full text]
  • The Effectiveness of Light Therapy for College Student Depression
    Journal of College Student Psychotherapy ISSN: 8756-8225 (Print) 1540-4730 (Online) Journal homepage: http://www.tandfonline.com/loi/wcsp20 The Effectiveness of Light Therapy for College Student Depression Lisa A. House & Barry Walton To cite this article: Lisa A. House & Barry Walton (2018) The Effectiveness of Light Therapy for College Student Depression, Journal of College Student Psychotherapy, 32:1, 42-52, DOI: 10.1080/87568225.2017.1321975 To link to this article: https://doi.org/10.1080/87568225.2017.1321975 Published online: 22 May 2017. Submit your article to this journal Article views: 745 View Crossmark data Full Terms & Conditions of access and use can be found at http://www.tandfonline.com/action/journalInformation?journalCode=wcsp20 JOURNAL OF COLLEGE STUDENT PSYCHOTHERAPY 2018, VOL. 32, NO. 1, 42–52 https://doi.org/10.1080/87568225.2017.1321975 BRIEF REPORT The Effectiveness of Light Therapy for College Student Depression Lisa A. Housea and Barry Waltonb aCenter for Counseling and Human Development, Millersville University, Millersville, Pennsylvania, USA; bInformation Systems Services, Millersville University, Millersville, Pennsylvania, USA ABSTRACT KEYWORDS There is a growing number of students on college campuses College student mental with mental health problems and college counseling services health; depression; light box; are reporting significant increases in student demand for light therapy; seasonal counseling. Depression, a mental illness consisting of pro- affective disorder found sadness, fatigue, and irritability, as well as low motiva- tion, poor academic performance, and suicidal behaviors, is one of the top presenting concerns for students who seek help. This study investigates the effectiveness of light therapy in a sample of 79 college students who suffer from depres- sion.
    [Show full text]
  • Adjunctive Bright Light Therapy for Bipolar Depression: a Randomized Double-Blind Placebo-Controlled Trial
    ARTICLES Adjunctive Bright Light Therapy for Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Trial Dorothy K. Sit, M.D., James McGowan, B.A., Christopher Wiltrout, B.S., Rasim Somer Diler, M.D., John (Jesse) Dills, M.L.S., James Luther, M.A., Amy Yang, M.S., Jody D. Ciolino, Ph.D., Howard Seltman, M.D., Ph.D., Stephen R. Wisniewski, Ph.D., Michael Terman, Ph.D., Katherine L. Wisner, M.D., M.S. Objective: Patients with bipolar disorder have recurrent major Pittsburgh Sleep Quality Index. Remission was defined as depression, residual mood symptoms, and limited treatment having a SIGH-ADS score of 8 or less. options. Building on promising pilot data, the authors conducted a6-weekrandomizeddouble-blindplacebo-controlledtrialto Results: At baseline, both groups had moderate depression investigate the efficacy of adjunctive bright light therapy at and no hypomanic or manic symptoms. Compared with the midday for bipolar depression. The aims were to determine placebo light group, the group treated with bright white light remission rate, depression symptom level, and rate of mood experienced a significantly higher remission rate (68.2% com- polarity switch, as well as to explore sleep quality. pared with 22.2%; adjusted odds ratio=12.6) at weeks 4–6and significantly lower depression scores (9.2 [SD=6.6] compared Method: The study enrolled depressed adults with bipolar I or with14.9[SD=9.2]; adjusted b=–5.91) at the endpoint visit. No II disorder who were receiving stable dosages of antimanic mood polarity switches were observed. Sleep quality improved medication (excluding patients with hypomania or mania, mixed in both groups and did not differ significantly between them.
    [Show full text]
  • Light-Therapy Applications for DSM-IV-TR Disease Entities
    Eur. J. Psychiat. Vol. 23, N.° 3, (166-176) 2009 Keywords: Seasonal affective disorder (SAD); Light therapy; Phototherapy. Light-therapy applications for DSM-IV-TR disease entities Mercedes Paino Eduardo Fonseca-Pedrero Manuel Bousoño Serafín Lemos-Giráldez Department of Psychology. University of Oviedo Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Ministry of Science and Innovation SPAIN ABSTRACT – Background and Objectives: Recent decades have seen significant ad- vances in the knowledge of pathogenesis of mood disorders, as well as of other conditions directly or indirectly related to such diseases. Such progress has led to the emergence of new treatments, such as bright light therapy, based on the discovery of the therapeutic ef- fects of exposure to bright light with the so-called seasonal affective disorder (SAD), a DSM seasonal pattern specifier linked to major depression and bipolar disorder recurrent describing the course of illness during seasons. The goal of the present work is to review the potential clinical applications of phototherapy, including SAD, obsessive-compulsive disorder, bulimia, premenstrual syndrome, non seasonal major depression, sleep disor- ders, jet-lag, dementia, normal populations and in primary care. Methods: A systematic review of the literature about this matter since the early Rosen- thal’s group observations has been carried out. Results: A considerable number of studies has been published about this therapeutic approach, pointing that not only depression but also other pathologies that may follow a seasonal pattern could benefit from phototherapy integrated with more standard treat- ments, as well as other disorders directly or indirectly related to mood, and even another conditions without a seasonal pattern.
    [Show full text]
  • Augmentation of Light Therapy in Difficult-To-Treat Depressed Patients: an Open-Label Trial in Both Unipolar and Bipolar Patients
    Journal name: Neuropsychiatric Disease and Treatment Article Designation: Original Research Year: 2015 Volume: 11 Neuropsychiatric Disease and Treatment Dovepress Running head verso: Camardese et al Running head recto: Light therapy in DTD unipolar and bipolar depressed patients open access to scientific and medical research DOI: http://dx.doi.org/10.2147/NDT.S74861 Open Access Full Text Article ORIGINAL RESEARCH Augmentation of light therapy in difficult-to-treat depressed patients: an open-label trial in both unipolar and bipolar patients Giovanni Camardese1 Objectives: We investigated the clinical benefits of bright light therapy (BLT) as an adjunct Beniamino Leone1 treatment to ongoing psychopharmacotherapy, both in unipolar and bipolar difficult-to-treat Riccardo Serrani1 depressed (DTD) outpatients. Coco Walstra1 Methods: In an open-label study, 31 depressed outpatients (16 unipolar and 15 bipolar) Marco Di Nicola1 were included to undergo 3 weeks of BLT. Twenty-five completed the treatment and 5-week Giacomo Della Marca2 follow-up. Clinical outcomes were evaluated by the Hamilton Depression Rat- Pietro Bria1 Main outcome measures: ing Scale (HDRS). The Snaith–Hamilton Pleasure Scale and the Depression Retardation Rating Luigi Janiri1 Scale were used to assess changes in anhedonia and psychomotor retardation, respectively. 1 For personal use only. Institute of Psychiatry and Results: The adjunctive BLT seemed to influence the course of the depressive episode, and a Psychology, 2Institute of Neurology, Catholic University of the Sacred statistically significant reduction in HDRS scores was reported since the first week of therapy. Heart, Rome, Italy The treatment was well-tolerated, and no patients presented clinical signs of (hypo)manic switch during the overall treatment period.
    [Show full text]